Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



EVALUATION OF INTERLEUKIN-12 AND INTERLEUKIN-4 LEVELS IN MULTIBACILLARY-TYPE LEPROSY PATIENT 12 MONTHS AFTER RIFAMPICIN OFLOXACIN MINOCYCLINE COMBINATION THERAPY

Eman Arif Rahman, Sri Vitayani Muchtar, Farida Tabri, Siswanto Wahab, Anni Adriani, Arifin Seweng, Rizalinda Sjahril.




Abstract
Cited by 0 Articles

Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae. In leprosy, cell-mediated immune responses are an important aspect of host resistance to mycobacterial infections and allegedly governed by anequilibrium between type 1 cytokines including Interleukin-12 (IL-12); with type 2 cytokines such as Interleukin-4 (IL-4). Currently, the World Health Organization (WHO) recommends 3 leprosy treatment regimens, one of them is Rifampicin Ofloxacin Minocycline (ROM). To date, studies on the effects of ROM on leprosy have been limited, none have specifically assessed the effects of ROM on specific immune systems, especially cytokines.
Methods: The study was conducted by prospective research method. The sample of this research were all multibacillary (MB) type of leprosy patients according to WHO classification who had received ROM therapy and recorded as the patient at research location and had medical record previous of interleukin-12 and interleukin-4 levels. After 12 months of ROM therapy, blood samples were collected and calculated using the Enzyme-Linked Immunosorbent Assay (ELISA) using the Quantikine® high sensitivity (HSv) kit.
Results: There was a statistically significant increase in IL-4 after 12 months of a 3-months-ROM therapy. In contrast, the levels of IL-12 after 12 months showed significant decreases.
Conclusions: Increased levels of IL-4 and decreased IL-12 can be caused by many factors. Therefore, further research with a closer supervision is required.

Key words: Leprosy, Rifampicin Ofloxacin Minocycline therapy, Interleukin-12, Interleukin-4






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.